跳至主要内容
临床试验/NCT00180856
NCT00180856已完成2 期

A Phase II Study of Radiofrequency Ablation of Lung Tumors

Gustave Roussy, Cancer Campus, Grand Paris2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2002年1月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
2
主要终点
Incomplete local treatment

研究概览

简要总结

Radiofrequency ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. Animal studies have demonstrated that radiofrequency can fully ablate lung tumors in animal models. We set up a prospective study to evaluate the local efficacy of radiofrequency ablation of lung neoplasms. The aim of the study is to prospectively evaluate local efficacy with a minimal follow-up of one year, tolerance, lung disease-free survival and survival after radiofrequency ablation of lung tumors (primary lung cancer or lung metastases).

详细描述

Radiofrequency (RF) ablation has achieved impressive results in the treatment of unresectable primary and metastatic liver cancer. Animal studies have demonstrated that RF can fully ablate lung tumors in animal models. We set up a prospective study to evaluate the local efficacy of radiofrequency ablation of lung neoplasms with a minimal follow-up of one year. The primary endpoint was to determine the rate of incomplete local treatment at 1 year. The secondary endpoints were to evaluate tolerance, survival, disease-free survival and lung tumor-free survival. Patients are followed-up by CT scan examination at day 1 or 2 before discharge from the hospital, then at 2, 4, 6, 9 and 12 months and then at 2 years

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Unilateral or bilateral unresectable primary or metastatic lung tumors <= 40 mm and a number of tumor <=5
  • Tumors located more than 1 cm from the hilum, and not involving soft tissues or mediastinum.
  • Malignancy histologically proven for pulmonary nodules in patients with no history of cancer outside the lung.
  • Lung tumors in patients with a known distant cancer history, has to be either histologically proven or a demonstrated change in size of at least 25% in their largest diameter is required on CT during the previous year
  • Pretreatment imaging work-up within 4 weeks of scheduled RF ablation (at least a chest CT and an abdomino-pelvic CT)
  • If a tumor is found outside the lung, it has to be amenable to complete eradication with RF or RF plus surgery
  • Lung spirometry within 4 weeks of treatment with a FEV1 >= 1 liter
  • Written informed consent.

排除标准

  • Uncorrectable coagulopathy with a prothrombin time greater than 1.5 and a platelet count below 106/mm3

结局指标

主要结局

Incomplete local treatment

次要结局

  • Survival
  • Lung disease-free survival

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验